The FDA on February 26, 2016 approved GAZYVA® for use in combination with Bendamustine followed by GAZYVA® monotherapy for the treatment of patients with Follicular Lymphoma (FL) who relapsed after, or are refractory to, a RITUXAN® (Rituximab) containing regimen. GAZYVA® was previously approved for use in combination with Chlorambucil for the treatment of patients with previously untreated Chronic Lymphocytic Leukemia. GAZYVA® injection is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
